355 related articles for article (PubMed ID: 28778361)
1. Antibiotic Dosing in Continuous Renal Replacement Therapy.
Shaw AR; Mueller BA
Adv Chronic Kidney Dis; 2017 Jul; 24(4):219-227. PubMed ID: 28778361
[TBL] [Abstract][Full Text] [Related]
2. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
Roberts DM; Roberts JA; Roberts MS; Liu X; Nair P; Cole L; Lipman J; Bellomo R;
Crit Care Med; 2012 May; 40(5):1523-8. PubMed ID: 22511133
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic Exposure Profiles in Trials Comparing Intensity of Continuous Renal Replacement Therapy.
Jang SM; Pai MP; Shaw AR; Mueller BA
Crit Care Med; 2019 Nov; 47(11):e863-e871. PubMed ID: 31397714
[TBL] [Abstract][Full Text] [Related]
4. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*.
Jamal JA; Udy AA; Lipman J; Roberts JA
Crit Care Med; 2014 Jul; 42(7):1640-50. PubMed ID: 24674926
[TBL] [Abstract][Full Text] [Related]
5. Case-control study of drug monitoring of β-lactams in obese critically ill patients.
Hites M; Taccone FS; Wolff F; Cotton F; Beumier M; De Backer D; Roisin S; Lorent S; Surin R; Seyler L; Vincent JL; Jacobs F
Antimicrob Agents Chemother; 2013 Feb; 57(2):708-15. PubMed ID: 23147743
[TBL] [Abstract][Full Text] [Related]
6. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
Taccone FS; Laterre PF; Dugernier T; Spapen H; Delattre I; Wittebole X; De Backer D; Layeux B; Wallemacq P; Vincent JL; Jacobs F
Crit Care; 2010; 14(4):R126. PubMed ID: 20594297
[TBL] [Abstract][Full Text] [Related]
7. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
Carlier M; Carrette S; Roberts JA; Stove V; Verstraete A; Hoste E; Depuydt P; Decruyenaere J; Lipman J; Wallis SC; De Waele JJ
Crit Care; 2013 May; 17(3):R84. PubMed ID: 23642005
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT.
Bauer SR; Salem C; Connor MJ; Groszek J; Taylor ME; Wei P; Tolwani AJ; Fissell WH
Clin J Am Soc Nephrol; 2012 Mar; 7(3):452-7. PubMed ID: 22282479
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
Asín-Prieto E; Rodríguez-Gascón A; Trocóniz IF; Soraluce A; Maynar J; Sánchez-Izquierdo JÁ; Isla A
J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
[TBL] [Abstract][Full Text] [Related]
10. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.
Seyler L; Cotton F; Taccone FS; De Backer D; Macours P; Vincent JL; Jacobs F
Crit Care; 2011; 15(3):R137. PubMed ID: 21649882
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
Ong CT; Kuti JL; Nicolau DP;
Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
[TBL] [Abstract][Full Text] [Related]
12. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
Sturm AW; Allen N; Rafferty KD; Fish DN; Toschlog E; Newell M; Waibel B
Pharmacotherapy; 2014 Jan; 34(1):28-35. PubMed ID: 23864417
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
Cies JJ; Shankar V; Schlichting C; Kuti JL
Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
[TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
[TBL] [Abstract][Full Text] [Related]
16. An optimal extended-infusion dosing of cefepime and ceftazidime in critically ill patients with continuous renal replacement therapy.
Sember AM; LoFaso ME; Lewis SJ
J Crit Care; 2022 Jun; 69():154011. PubMed ID: 35202996
[TBL] [Abstract][Full Text] [Related]
17. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
[TBL] [Abstract][Full Text] [Related]
18. Piperacillin-tazobactam dosing in anuric acute kidney injury patients receiving continuous renal replacement therapy.
Rungkitwattanakul D; Charoensareerat T; Chaichoke E; Rakamthong T; Srisang P; Pattharachayakul S; Srisawat N; Chaijamorn W
Semin Dial; 2023; 36(6):468-476. PubMed ID: 36807546
[TBL] [Abstract][Full Text] [Related]
19. Optimal antipseudomonal ꞵ-lactam drug dosing recommendations in critically-ill Asian patients receiving CRRT.
Jang SM; Lewis SJ; Rhie SJ
J Crit Care; 2022 Dec; 72():154172. PubMed ID: 36270240
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
Kotapati S; Kuti JL; Nicolau DP
Surg Infect (Larchmt); 2005; 6(3):297-304. PubMed ID: 16201939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]